

## Centre For Health Economics Seminar Series 2019

### The use of real-world data to improve precision oncology

Presenter: Professor Maarten IJzerman  
Date: Wednesday 24 April 2019  
Time: 12.00pm - 1.00pm  
Venue: Room H.921 Caulfield campus



#### Abstract

There is an increasing interest in the use of (real-world) clinical registries, administrative datasets and various other datasets (such as hospital admissions and the pharmacy benefits) in health economics and outcomes research. This presentation will discuss opportunities and examples of data-driven research initiatives to evaluate treatment variation and understand how we can improve outcomes for patients. This presentation's focus is on the use of real-world data for the economic evaluation of precision oncology applications (e.g. treatment sequencing in metastatic disease) and cancer diagnostics.

#### Presenter

**Maarten J. IJzerman** is the VCCC professor and head of Cancer Health Services Research in the University of Melbourne, Centre for Cancer Research and Centre for Health Policy. He also holds a fractional appointment as a professor in the University of Twente supervising a research program on the health economic impact of liquid biopsies in cancer management. Maarten is co-chairing the data-driven cancer health services research hub and is using linked data-sets and clinical registries for his research on dynamic treatment pathways for cancer patients.

Maarten is a (co-)PI on several investigator initiated studies such as the CTC-STOP trial (ICR, London) and STIC trial (Institut Curie, Paris) evaluating the clinical use of circulating tumor cells. He is a co-PI of the Canadian-Dutch UCAN-CANDU and the Genome Canada funded UCAN-CURE study, working on the application of precision medicine in juvenile arthritis. Maarten is a global leader in the International Society for Pharmacoeconomics and Outcomes Research, and as such promotes active collaboration between ISPOR and the European Cancer Organisation (ECCO) on systems analysis of value-based cancer care. In 2016, he joined the European Society for Medical Oncology (ESMO) Cancer Medicines working group dealing with the disparities in access to cancer drugs. Maarten is a board member of two Dutch hospitals, mainly responsible for quality and safety and strategy/innovation. In Australia, he is a member of the Biogrid business advisory board, the MACH Health Services and Clinical Informatics Committee and the Health Services Improvement and Sustainability committee of the Australian Health Research Alliance (AHRA).

#### VISITORS ARE MOST WELCOME

The Seminar Series is free of charge. For further information please phone 9905 0733 or email

[che-enquiries@monash.edu](mailto:che-enquiries@monash.edu)

#### Over 25 Years of Health Economics at Monash University